We investigated a series of Tween 85 modified low molecular weight polyethylenimine (LPEI, 0.8k/1.2k/2.0k)-copolymers (Zs) through simple formulation and covalent conjugation with phosphorodiamidate morpholino oligomer (PMO) for their potential to enhance delivery in vitro and in dystrophic mdx mice. Z polymers significantly enhanced PMO-induced exon-skipping in a GFP reporter-based cell culture system. Application of optimized formulations of Zs with PMO targeted to dystrophin exon 23 demonstrated a significant increase in exon-skipping efficiency in mdx mice. Consistent with our observations in vitro, optimization of molecular size and hydropholic-lipopholic balance (HLB) of polymers are important factors to achieve enhanced PMO delivery ...
Duchenne muscular dystrophy (DMD) is a severe hereditary neuromuscular disorder caused by mutations ...
Duchenne muscular dystrophy (DMD) is a severe neuromuscular disorder caused by mutations in the dyst...
Ssion. TA muscles were given 10 twice-weekly intramuscular injections of 5 μg of ESO complexed with ...
Mingxing Wang, Bo Wu, Jason D Tucker, Peijuan Lu, Qilong Lu Department of Neurology, McColl-Lockwoo...
EG550), or CG-PEI2K(PEG5K)copolymers, and harvested 3 wks after the first injection. Number of dystr...
EG550), or CG-PEI2K(PEG5K)copolymers, and harvested 3 wks after the first injection. Number of dystr...
Antisense oligonucleotide therapy for Duchenne muscular dystrophy has shown great potential in precl...
harvested 3 wks after the first injection. Dystrophin immunolabeling (Hoechst dye counterstained) at...
Duchenne muscular dystrophy (DMD) is a genetic disease caused by a mutation in the X-linked Dytrophi...
Ons of either 1 μg () or 5 μg () of ESO complexed with the NG-PEI2K(PEG550)copolymer. Muscles were h...
harvested 3 wks after the first injection. Dystrophin immunolabeling (Hoechst dye counterstained) at...
A series of poly(esteramine)s (PEAs) constructed from low molecular weight polyethyleneimine (LPEI) ...
�g of ESO per injection (3, 15, 30, and 60 μg total) and harvested 3 wks after the first injection. ...
AbstractExon-skipping efficacies of phosphodiamidate morpholino oligomers (PMOs) or the conjugates o...
Abstract Duchenne muscular dystrophy (DMD) is a severe hereditary neuromuscular disorder caused by m...
Duchenne muscular dystrophy (DMD) is a severe hereditary neuromuscular disorder caused by mutations ...
Duchenne muscular dystrophy (DMD) is a severe neuromuscular disorder caused by mutations in the dyst...
Ssion. TA muscles were given 10 twice-weekly intramuscular injections of 5 μg of ESO complexed with ...
Mingxing Wang, Bo Wu, Jason D Tucker, Peijuan Lu, Qilong Lu Department of Neurology, McColl-Lockwoo...
EG550), or CG-PEI2K(PEG5K)copolymers, and harvested 3 wks after the first injection. Number of dystr...
EG550), or CG-PEI2K(PEG5K)copolymers, and harvested 3 wks after the first injection. Number of dystr...
Antisense oligonucleotide therapy for Duchenne muscular dystrophy has shown great potential in precl...
harvested 3 wks after the first injection. Dystrophin immunolabeling (Hoechst dye counterstained) at...
Duchenne muscular dystrophy (DMD) is a genetic disease caused by a mutation in the X-linked Dytrophi...
Ons of either 1 μg () or 5 μg () of ESO complexed with the NG-PEI2K(PEG550)copolymer. Muscles were h...
harvested 3 wks after the first injection. Dystrophin immunolabeling (Hoechst dye counterstained) at...
A series of poly(esteramine)s (PEAs) constructed from low molecular weight polyethyleneimine (LPEI) ...
�g of ESO per injection (3, 15, 30, and 60 μg total) and harvested 3 wks after the first injection. ...
AbstractExon-skipping efficacies of phosphodiamidate morpholino oligomers (PMOs) or the conjugates o...
Abstract Duchenne muscular dystrophy (DMD) is a severe hereditary neuromuscular disorder caused by m...
Duchenne muscular dystrophy (DMD) is a severe hereditary neuromuscular disorder caused by mutations ...
Duchenne muscular dystrophy (DMD) is a severe neuromuscular disorder caused by mutations in the dyst...
Ssion. TA muscles were given 10 twice-weekly intramuscular injections of 5 μg of ESO complexed with ...